Biotage Company Overview August 2023

Dr. Olof Nord, Executive Vice President Business Development



HumanKind Unlimited

Biotage – A Global Life Science company





Products sold in more than +80 countries



Direct sales revenue 96%




Aftermarket 2023 split 64% / 36%

~ 4500 customers




18 locations globally & 6 **R&D** sites



Where we come from





Biotage's Strategic focus on Biologics & Advanced Therapeutics

Recent acquisitions strengthen our offering in the biologics and advanced therapeutic segment.

- Biologics outpaced small-molecule FDA-approvals for the first time in 2022*
- Advanced therapeutics accounted for about half of the biologic FDA-approvals*
- Oncology dominates the pipeline league tables and research into rare diseases has generated important new therapies**.




solution at dbio



<u>*Source: Nature, 9 Jan 2023</u> <u>**Evaluate Pharma, Oct 2022</u> The Astrea Bioseparations transaction is conditional upon shareholder approval.

Biotage – A Global Life Science Tools & Service Provider Biotage



A quality **Workflow Modality, Tools & Service Provider** providing the shovels to the **Pharma, BioPharma** and **Diagnostic** Industry




 Biotage is providing the picks, screwdrivers and shovels to the Prospectors = Pharma, BioPharma and Diagnostic Industry

A Global Life Science Tools & Service Provider



Focus on High-Growth Blue Ocean niches in our Customers' Workflow with Buy-Partner-Build




Biotage - Transforming mix towards dynamically growing Bioproduction & Bioprocessing






Astrea Bisoseparations moves Biotage naturally into High-Growth Markets for Biomolecules









HumanKind Unlimited

